Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19797375 | 0.94 | NPSR1 (0.36) | NPSR1PGRLMNAHTTMAPT | |
| SCHEMBL19797362 | 0.92 | NPSR1 (0.36) | NPSR1PGRLMNAHTTMAPT | |
| SCHEMBL13231589 | 0.83 | LMNA (0.39) | PGRLMNAHTTMAPTUSP2 | |
| SCHEMBL19797360 | 0.80 | EGLN1 (0.33) | PGRLMNAHTTMAPTMEN1 | |
| SCHEMBL19797397 | 0.78 | — | — | |
| SCHEMBL19797352 | 0.77 | EGLN1 (0.33) | PGRLMNAHTTMAPTMEN1 | |
| SCHEMBL19797355 | 0.77 | EGLN1 (0.34) | NPSR1PGRLMNAHTTMAPT | |
| SCHEMBL13231623 | 0.77 | PGR (0.38) | NPSR1PGRLMNAHTTMAPT | |
| SCHEMBL19797365 | 0.77 | KMT2A (0.34) | NPSR1PGRLMNAHTTMAPT | |
| SCHEMBL19797354 | 0.76 | LMNA (0.40) | LMNAHTTMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10388889-B2 | Substituted phosphines as components of organic light-emitting devices | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-08-20 | — | — | US | disclosed |
| US-20180026206-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-01-25 | — | — | US | disclosed |
| US-20180026206-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180026206-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CYP1A1, CYP1B1 | NPSR1 4005/4885PGR 1163/4885LMNA 2798/4885 |
| US-10388889-B2 | Substituted phosphines as components of organic light-emitting devices | CRY1, CRY2, PER2 | NPSR1 2792/4885PGR 404/4885LMNA 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.